Summary:  Phase III Pivotal study did not fulfill a criterion for early         
stopping; Independent Data Monitoring Committee has recommended that the trial  
should continue to enroll patients.                                             

Copenhagen, Denmark; January 5, 2009 - Genmab A/S (OMX: GEN) announced today    
that the interim survival analysis of the Phase III pivotal study investigating 
zalutumumab (HuMax-EGFr(R)) in refractory head and neck cancer patients did not 
fulfill a criterion for early stopping after half the trial has been completed. 
An Independent Data Monitoring Committee (IDMC) has evaluated the interim       
results and concluded that the benefit-risk profile of zalutumumab is           
acceptable. The IDMC recommended that the trial should continue to enroll up to 
a maximum of 273 patients and a final analysis performed.                       

As of today, 212 patients have been randomized and the final analysis will take 
place once 231 deaths have occurred.                                            

"We are pleased that this study will continue and are optimistic that the full  
study results will show extended survival in patients with advanced head and    
neck cancer," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.  

About the trial                                                                 
The pivotal study will include a maximum of 273 patients with squamous cell     
carcinoma of the head and neck (SCCHN) who are refractory to or intolerant of   
standard platinum-based chemotherapy.  Patients in the study will be randomized 
into two treatment groups: zalutumumab in combination with best supportive care 
or best supportive care alone. Patients treated with zalutumumab in combination 
with best supportive care will receive an initial dose of 8mg/kg of zalutumumab,
followed by weekly infusions of a maintenance dose until disease progression.   
The maintenance dose will be adjusted as necessary until the patient develops a 
dose limiting skin rash, up to a maximum dose of 16 mg/kg of zalutumumab.       
Disease status will be assessed every 8 weeks by CT scan or MRI according to    
RECIST criteria until disease progression and patients will be followed for     
The objective of the study is to evaluate the efficacy of zalutumumab in        
combination with best supportive care as compared to best supportive care alone 
in terms of overall survival. The primary endpoint in the study is overall      
survival from randomization until death.                                        

Conference Call                                                                 
Genmab will hold a conference call to discuss these results today, January 5,   
2009 at:                                                                        
6:00 pm CET                                                                     
5:00 pm GMT                                                                     
12:00 pm EST                                                                    
The conference call will be held in English.                                    

The dial in numbers are as follows:                                             
+1 877-856-1969 (in the US) and ask for the Genmab conference call              
+1 719-325-4814 (outside the US) and ask for the Genmab conference call         

To listen to a live webcast of the call please visit            

About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for the potential treatment of cancer.        
Genmab's world class discovery, development and manufacturing teams are using   
cutting-edge technology to create and develop products to address unmet medical 
needs.  Our primary goal is to improve the lives of patients who are in urgent  
need of new treatment options.  For more information on Genmab's products and   
technology, visit                                               

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. For a     
further discussion of these risks, please refer to the section “Risk Management”
in Genmab's Annual Report, which is available on  Genmab does   
not undertake any obligation to update or revise forward looking statements in  
this press release nor to confirm such statements in relation to actual results,
unless required by law.                                                         

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM);
HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM)   
and UniBody(R) are all trademarks of Genmab A/S.                                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E:                                              
Stock Exchange Release no. 01/2009